Pascal Soriot, AstraZeneca CEO (via Getty images)
October 20, 2021 10:24 AM EDTUpdated 02:12 PM
R&D
FDA+

FDA slaps As­traZeneca's MCL-1 can­cer drug with a hold af­ter safe­ty is­sue — 2 years af­ter Am­gen axed a trou­bled ri­val

John Carroll

Editor & Founder

There are new ques­tions be­ing posed about a class of can­cer drugs in the wake of the sec­ond FDA-en­forced clin­i­cal hold in the field. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ab­b­Vie makes an­oth­er small I&I ac­qui­si­tion, buy­ing Nim­ble for $200M

Bi­cy­cle Ther­a­peu­tics stock sinks fol­low­ing re­lease of topline da­ta, post-hoc analy­ses

McK­in­sey hit with a $650M fine for de­ceiv­ing US about opi­oid con­sult­ing work

EMA's com­mit­tee says ex­pand­ed la­bel for Lil­ly's Moun­jaro in­to sleep ap­nea not nec­es­sary

Gilead names Di­et­mar Berg­er CMO as it eyes R&D re­set

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times